logo
Plus   Neg
Share
Email

Stars Group Slashes FY19 Outlook - Quick Facts

While reporting financial results for the second quarter, Stars Group, Inc. (TSG, TSGI.TO) on Monday slashed its adjusted earnings and revenue guidance for the full year 2019.

For fiscal 2019, the company now projects adjusted earnings in a range of $1.68 to $1.83 per share on revenues between $2.50 billion and $2.575 billion.

Previously, the company expected adjusted earnings in the range of $1.87 to $2.11 per share on revenues between $2.64 billion and $2.765 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.28 per share on revenues of $1.31 billion for the year. Analysts' estimates typically exclude special items.

Additionally, the Stars Group continues to expect to achieve the medium-term financial and leverage target ranges set out in late March, but now over the three to five year period from the currently slashed 2019 outlook range.

Over the next three to five year period, the company had projected annual adjusted earnings per share growth of at least 10 percent and annual constant currency revenue growth of 8 to 12 percent from the previous guidance range.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
RELATED NEWS
Follow RTT
>